JP2014510119A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510119A5
JP2014510119A5 JP2014503079A JP2014503079A JP2014510119A5 JP 2014510119 A5 JP2014510119 A5 JP 2014510119A5 JP 2014503079 A JP2014503079 A JP 2014503079A JP 2014503079 A JP2014503079 A JP 2014503079A JP 2014510119 A5 JP2014510119 A5 JP 2014510119A5
Authority
JP
Japan
Prior art keywords
agents
present
drugs
formula
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014503079A
Other languages
English (en)
Japanese (ja)
Other versions
JP5763834B2 (ja
JP2014510119A (ja
Filing date
Publication date
Priority claimed from EP11161111A external-priority patent/EP2508525A1/en
Application filed filed Critical
Publication of JP2014510119A publication Critical patent/JP2014510119A/ja
Publication of JP2014510119A5 publication Critical patent/JP2014510119A5/ja
Application granted granted Critical
Publication of JP5763834B2 publication Critical patent/JP5763834B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014503079A 2011-04-05 2012-03-29 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類 Expired - Fee Related JP5763834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP11161111.7 2011-04-05
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015091455A Division JP5826961B2 (ja) 2011-04-05 2015-04-28 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類

Publications (3)

Publication Number Publication Date
JP2014510119A JP2014510119A (ja) 2014-04-24
JP2014510119A5 true JP2014510119A5 (cg-RX-API-DMAC7.html) 2015-06-18
JP5763834B2 JP5763834B2 (ja) 2015-08-12

Family

ID=43984137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014503079A Expired - Fee Related JP5763834B2 (ja) 2011-04-05 2012-03-29 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類
JP2015091455A Expired - Fee Related JP5826961B2 (ja) 2011-04-05 2015-04-28 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015091455A Expired - Fee Related JP5826961B2 (ja) 2011-04-05 2015-04-28 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類

Country Status (42)

Country Link
US (2) US10383876B2 (cg-RX-API-DMAC7.html)
EP (2) EP2508525A1 (cg-RX-API-DMAC7.html)
JP (2) JP5763834B2 (cg-RX-API-DMAC7.html)
KR (1) KR101937501B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649091B (cg-RX-API-DMAC7.html)
AP (1) AP3709A (cg-RX-API-DMAC7.html)
AR (1) AR085718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012238891B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832123C (cg-RX-API-DMAC7.html)
CL (1) CL2013002870A1 (cg-RX-API-DMAC7.html)
CO (1) CO6781534A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130511A (cg-RX-API-DMAC7.html)
CU (1) CU24208B1 (cg-RX-API-DMAC7.html)
CY (1) CY1116231T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694508T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000223A (cg-RX-API-DMAC7.html)
EA (1) EA023646B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013006A (cg-RX-API-DMAC7.html)
ES (1) ES2529653T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300234A (cg-RX-API-DMAC7.html)
HR (1) HRP20150138T1 (cg-RX-API-DMAC7.html)
IL (1) IL228561A (cg-RX-API-DMAC7.html)
JO (1) JO2958B1 (cg-RX-API-DMAC7.html)
MA (1) MA35014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02021B (cg-RX-API-DMAC7.html)
MX (1) MX336057B (cg-RX-API-DMAC7.html)
MY (1) MY169452A (cg-RX-API-DMAC7.html)
PE (1) PE20141038A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502065A1 (cg-RX-API-DMAC7.html)
PL (1) PL2694508T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694508E (cg-RX-API-DMAC7.html)
RS (1) RS53811B1 (cg-RX-API-DMAC7.html)
SG (1) SG193595A1 (cg-RX-API-DMAC7.html)
SI (1) SI2694508T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500037B (cg-RX-API-DMAC7.html)
TN (1) TN2013000401A1 (cg-RX-API-DMAC7.html)
TW (2) TWI592158B (cg-RX-API-DMAC7.html)
UA (1) UA111604C2 (cg-RX-API-DMAC7.html)
UY (1) UY33985A (cg-RX-API-DMAC7.html)
WO (1) WO2012136553A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307105B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
KR20160019434A (ko) 2013-06-14 2016-02-19 바이엘 파마 악티엔게젤샤프트 항-tweakr 항체 및 그의 용도
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TN2018000271A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
TN2018000272A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022505325A (ja) * 2018-10-17 2022-01-14 サンド・アクチエンゲゼルシヤフト レボチロキシン及びジカルボン酸を含む共結晶
US12139491B2 (en) * 2018-12-27 2024-11-12 Holosmedic Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (cg-RX-API-DMAC7.html) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AP2015008750A0 (en) * 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин

Similar Documents

Publication Publication Date Title
Spreen et al. Long-acting injectable antiretrovirals for HIV treatment and prevention
ES2581834T3 (es) Formulación tópica para un inhibidor de JAK
JP5635075B2 (ja) 抗真菌医薬組成物
JP6224064B2 (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2019509276A5 (cg-RX-API-DMAC7.html)
JP2002534382A (ja) タキサン類の薬学的調合物
FI3577124T3 (fi) Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
SI2953948T1 (en) Fluorinated integrin antagonists
RU2018110363A (ru) Усилитель внутриклеточного атф
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
JP2020518629A5 (cg-RX-API-DMAC7.html)
CN104873461A (zh) 一种拉莫三嗪口服溶液的制备方法
EP2191820A1 (en) Pharmaceutical formulations of meloxicam
MX2021000403A (es) Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.
JP6450356B2 (ja) 液状医薬製剤
JP2020011903A (ja) 外用組成物
JP7186024B2 (ja) 外用医薬組成物
IL315130A (en) Compounds for use in the treatment of dystrophinopathies
RU2018114922A (ru) Лечение очаговой алопеции
JP7186025B2 (ja) 外用医薬組成物
TWI649097B (zh) 乙醯胺酚之可注射製劑
ES2631603T3 (es) Pomada con excelente estabilidad de formulación
BR112022012363A2 (pt) Composições farmacêuticas compreendendo um inibidor de jak quinase, método para preparar e uso das mesmas
TWI673050B (zh) 外用醫藥組成物